Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2025 20:05 ET | Source: Abinopharm, Inc.

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health
March 24, 2025 15:35 ET | Source: Abinopharm, Inc.

Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their GRAS notification of Dr.Ergo®Ergothioneine

Abinopharm, Inc. and our partner, EGT Synbio, announced our Ergothioneine ingredient received GRAS status from FDA, the 2nd GRAS for Ergothioneine in US.
February 05, 2024 04:00 ET | Source: Blue California Ingredients

Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep

Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
December 10, 2020 04:58 ET | Source: Blue California ingredients

Signs of Healthy Aging Found in Ergothioneine Telomere Study

RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements, demonstrated Blue California’s ErgoActive® ergothioneine helped...
July 14, 2020 17:37 ET | Source: Blue California Ingredients

Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19

Rancho Santa Margarita, Calif and Bedford, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Blue California, a science-based, innovative ingredient solution provider, has just filed for a patent on...
November 02, 2016 15:20 ET | Source: Entia Biosciences, Inc.

Entia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic Uses

PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title...
October 06, 2016 12:52 ET | Source: Entia Biosciences, Inc.

Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting

PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical...
September 26, 2016 08:30 ET | Source: Entia Biosciences, Inc.

Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months

PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected...
December 21, 2015 15:12 ET | Source: Entia Biosciences, Inc.

UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.

PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...
December 21, 2015 08:50 ET | Source: Entia Biosciences, Inc.

Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.

PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...